A Phase 1/2 interventional study of Sintilimab in HIV, AIDS and Immune Checkpoint Inhibitors, sponsored by Shanghai Public Health Clinical Center. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Shanghai Public Health Clinical Center · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Acquired Immunodeficiency Syndrome with a site in China — 21 open to participants now, 24 under way, 1 of them phase 3. Acquired Immunodeficiency Syndrome · China.
Among the 87 studies in Acquired Immunodeficiency Syndrome with a site in China, this one is the 46th largest by planned enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2026, is one of 8 in phase 1/2, reaches primary completion later than 22 of the 23 other live ones, and was the 81st registered.
3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →21 of the 87 studies in Acquired Immunodeficiency Syndrome with a site in China are open now. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 40+
Cell Energy Life Sciences Group Co. LTD · Sites in China
Ages 18–65
Guangzhou 8th People's Hospital · Sites in China
Ages 18–65
Guangzhou 8th People's Hospital · Sites in China
Ages 18–65
Guangzhou 8th People's Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 15 · Phase 3 8 · Phase 4 4
First in 2005; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 96 across 2,254 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 108 across the 68 interventional studies, 400 across the 18 observational. Of the 33 that completed or were terminated, 7 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 87 have an industry lead sponsor. The 10 most frequent:
Shanghai Public Health Clinical Center is the lead sponsor of 38 studies on the registry; 11 are open to participants now.
Shanghai Public Health Clinical Center has 8 studies filed under Acquired Immunodeficiency Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Acquired Immunodeficiency Syndrome with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07519538Southwest Medical UniversitySouthern Sichuan HIV Cohort Study Protocol | 2027-04-30 |
| NCT07577986First Affiliated Hospital of Zhejiang UniversityA Safety and Efficacy Trial of Chidamide Combined With NKG2D CAR-NK Cell Therapy for Reducing the HIV Viral Reservoir | 2027-05-01 |
| NCT07711210Jiangsu Aidea Pharmaceutical Group Co., Ltd.Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations | 2027-06-30 |
| NCT05939167Cell Energy Life Sciences Group Co. LTDMesenchymal Stem Cells Treatment for AIDS Patients at Late Stage | 2027-07-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 87 studies in Acquired Immunodeficiency Syndrome with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This prospective, single-arm, open-label study aims to evaluate the efficacy and safety of a PD-1 inhibitor (Sintilimab) combined with standard anti-infective therapy in patients with advanced HIV disease (AHD) who are suffering from refractory opportunistic infections (OIs).
Despite effective antiretroviral therapy (ART), some HIV patients develop severe, hard-to-treat infections (such as CMV, PCP, Tuberculosis, etc.) that do not respond to standard antimicrobial treatments. This is often due to a condition called "immune exhaustion," where the body's infection-fighting T-cells become inactive and express high levels of a protein called PD-1.
Sintilimab is an immune checkpoint inhibitor that blocks PD-1, effectively "waking up" the exhausted T-cells. While traditionally used for cancer, recent evidence suggests it can safely restore the immune system's ability to clear stubborn infections in HIV patients. In this study, eligible patients with refractory OIs and evidence of immune exhaustion will receive Sintilimab (200 mg intravenously every 3 weeks for a total of 3 doses) alongside their regular treatments. Researchers will monitor patient safety, clinical improvement, and immunological recovery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age ≥ 18 years. Confirmed -1 infection.
Must have at least one opportunistic infection meeting the "" criteria after currently available standard anti-infective treatment, defined as follows:
High expression on peripheral CD8+ T cells (>25%) OR weak pathogen-specific ELISpot response (\<50 SFCs/10\^6 cells).
Agreement to use highly effective during the study and for 6 months after the end of the trial.
Voluntary signing of .
Exclusion Criteria:
History of active disease or autoimmune disease requiring systemic treatment.
Prior organ transplantation or hematopoietic stem cell transplantation. Pregnant or lactating women. Known allergy or anti-drug antibodies to the study drug or its . Prior treatment or exposure to any other . Received immunomodulatory or therapy (excluding ) within 24 weeks prior to the first dose of the study drug.
Psychiatric disorders or substance abuse that may interfere with the trial. Other severe medical conditions deemed by the investigator as unsuitable for trial participation (e.g., uncontrolled severe heart, liver, or renal failure).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with advanced HIV disease and refractory opportunistic infections receive Sintilimab combined with standard anti-infective therapy and antiretroviral therapy (ART).
Drug: Sintilimab
Sintilimab 200 mg dissolved in 100 ml normal saline, administered via intravenous infusion (60 minutes) once every 3 weeks for a total of 3 doses (Days 1, 22, and 43).
Pathogen Clearance Rate
The proportion of patients achieving microbiological clearance (e.g., negative culture or negative PCR) of the specific refractory opportunistic infection.
Time frame: From enrollment to the end of treatment at 9 weeks
Patient Mortality Rate
The proportion of patients who die from any cause during the study period.
Time frame: From enrollment to the end of treatment at 9 weeks
Incidence of Treatment-Related Adverse Events (TRAEs)
Safety will be assessed by recording the incidence and severity of adverse events related to the study drug, graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time frame: From enrollment to the end of treatment at 9 weeks
Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in the published article will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will become available beginning 6 months and ending 36 months following article publication.
Access criteria: Data will be shared with qualified researchers who provide a methodologically sound proposal. Data will be used only to achieve the aims specified in the approved proposal. Proposals should be directed to the principal investigator or corresponding author via email. To gain access, data requestors will need to sign a formal data access agreement.
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Dec 2029, 43 months later.
Of 28 phase 1/2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 24. This study's planned 43 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sintilimab
Acquired Immunodeficiency Syndrome →
Shanghai Public Health Clinical Center